Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results GlobeNewswire - Wed Nov 13, 6:00AM CST

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 GlobeNewswire - Wed Nov 6, 7:00AM CST

1 'Strong Buy' Russell 2000 Stock With 188% Upside Potential Barchart - Tue Jul 2, 1:48PM CDT

As a part of the annual Russell Index reconstitution, this ‘Strong Buy’-rated penny stock is one of the new entrants to the Russell 2000 Index.

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race PressReach - Tue Oct 10, 2023

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN PR Newswire - Fri Aug 18, 2023